Thought-provoking interviews with industry experts on topics critical to the diagnosis, treatment, and prevention of progressive eye health
Promising results for faricimab revealed in TENAYA, LUCERNE year 2 data
Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.
New optics textbook aims to be a compendium resource for the topic
At AAO, Kamran Riaz, MD, discussed the new textbook, "Optics for the New Millennium," which is intended to be a compendium resource for ophthalmologists.
Moving beyond the drop: CEO provides updates on Oyster Point's pipeline
Jeff Nau, PhD, MMS, President and CEO of Oyster Point Pharmaceuticals, provides an appraisal of the company's pipeline as well as updates on recent innovations to hit the market.
ViaLase seeks to disrupt glaucoma treatment paradigm with new femtosecond laser treatment
Shawn O'Neil of ViaLase shares updates on the company's femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) treatment.
Contralateral eye study investigates iStent vs Hydrus stent for glaucoma
At AAO 2022, Mitch Shultz, MD, provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.
Trukera Medical rebranding allows team to expand into the broader corneal health market
Adam Szaronos, President and CEO of Trukera Medical, discusses the recent rebranding of TearLab as well as the launch of the ScoutPro Osmolarity System.
Assessing the effectiveness of netarsudil and episcleral blood flow in treatment-naive glaucoma suspects, hypertension subject
Osamah Saeedi, MD, MS, discusses his AAO 2022 talk titled, "Single-Cell Erythrocyte Tracking in Human Subjects Reveals Increase in Episcleral Venous Flow With Netarsudil 0.02%."
Higher rates of repeat corneal crosslinking need found in younger patients
At AAO 2022, Philip Dockery, MD, MPH, presents, "Effectiveness of corneal crosslinking in young patients."
Robot-assisted micro interventional glaucoma surgery reduces surgeon's tremors
Gautam Kamthan, MD, presented data at AAO 2022 regarding robot-assisted micro interventional glaucoma surgery.
Choosing among DSAEK, DMEK and DSO for endothelial keratoplasty
Kathryn A. Colby, MD, PhD, sits down with Ophthalmology Times to discuss her 2022 AAO presentation: "Endothelial Keratoplasty Should I Choose? DSAEK, DMEK, DSO"
Post hoc analysis of varenicline solution OC-01 shows promise for dry eye patients undergoing anticholinergic therapy
At AAO 2022 in Chicago, Illinios, Christopher Starr, MD, presented a talk entitled, "Efficacy of OC-01 (varenicline solution) (VNS) 0.03mg for Treatment of Dry Eye Disease Signs and Symptoms in Subjects With and Without Antidepressant/ Anxiolytic Use: Post-hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials."
Positive visual outcomes reported one year following monocular implantation of small aperture IOL
Mark H. Blecher, MD, dives into his AAO 2022 topic: "One-Year Visual Outcomes Following Monocular Implantation with a Small Aperture IOL."
Discussing how fluid dynamic affect visual acuity in wet macular degeneration
At the 2022 American Academy of Ophthalmology meeting, Justis Ehlers, MD, presented a talk titled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"
Reviewing the AAO cornea preferred practice patterns: Corneal edema, opacifications, ectasia and bacterial keratitis
David Hutton discusses the AAO 2022 presentation, "Corneal Edema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with speaker Francis S. Mah, MD.
Dispersive ophthalmic viscosurgical device found to be safe, effective in clinical trials
Mark Packer, MD, speaks on his 2022 AAO poster: "Safety and Effectiveness of a New FDA-Approved Dispersive Ophthalmic Viscosurgical Device."
Faricimab: YOSEMITE, RHINE treat-and-extend data illustrate favorable personalized treatment dynamics for the treatment of DME
Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."
Study: Using OCT Doppler to measure retinal blood flow biomarkers
The study assess retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.
Machine learning may predict optimal treatment regimen for patients with nAMD
Carlos Quezada Ruiz, MD, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”
GA therapy endpoints: Should tissue preservation be considered?
As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Karl Csaky, MD and Fredrick Ferris III, MD, identified in 2007—Dr. Csaky reinforces on the importance of preserving the central retinal tissue.
Safety data for at-home subcutaneous injection option for treatment of wet AMD, DME
Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.
Recent research suggests amblyopia has an affect on binocular vision
The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.
Study: Keratoconus patients experience challenges in getting timely corneal crosslinking that has led to permanent changes in their corneal structure
The study evaluates three separate cases, each which experiences irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the coronavirus pandemic.
Phase 3 PEACHTREE, AZALEA integrated study results presented at ARVO 2022: BCVA gains, CST reduction with Xipere
The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.
Use of CO-02 to stimulate the trigeminal nerve is a reasonable mechanism to help treat dry eyes
The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.
New advancements in IOL technology is exciting for presbyopia treatment
Catching up after ASCRS 2022, Ora's Caitlin Black, senior director and therapeutic area head of medical devices, talks about the next generation of ophthalmic device therapies and diagnostics, clinical trial updates and new innovations that are most exciting for presbyopia treatment.
ARMOR study evaluates antibiotic resistance in the treatment of staph infections
Penny Asbell, MD, FACS, MBA, discusses “Antibiotic Resistance among Ocular Staphylococcal Pathogens: Longitudinal Trends in the ARMOR Study."
New noninvasive technology shows positive safety and efficacy for the treatment of open angle glaucoma
Two year data shows a promising future for the OCD guided, noninvasive technology for glaucoma treatment.
Cataract classification method allows for higher success rates of cataract surgery
Alex Dastgheib, MD, ABO, discusses the findings of the paper, "325 Cases of Phacoemulsification in Blind Cataracts," presented at the 2022 ASCRS conference in Washington, DC. The paper won the Challenging Cases session during the meeting.
YOSEMITE and RHINE: 2-year results of faricimab in diabetic macular edema indicate reduced treatment burden
Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.
Johnson & Johnson Surgical Vision (JJV) continues innovation through new and elevated technologies
Allie Holmes, head of US marketing for Johnson & Johnson Surgical Vision, shares an update on what visioning the company is doing with their new and elevated technologies.
2 Clarke Drive Cranbury, NJ 08512